Clinical Trials Browser

Completed × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02458014 2025-09-23

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

Phase 2 Completed

36 enrolled

Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

NCT03340766 2024-10-17

HARBOUR

Phase 1 Completed

31 enrolled 29 charts

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00560794 2015-01-26

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

21 enrolled 19 charts

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00274742 2015-01-16

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Phase 1 Completed

76 enrolled 15 charts

Lymphoid

Bites and Stings, Lymphoma, Non-Hodgkin, Recurrence

Clinical Trials

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

HARBOUR

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL